Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Artelo Biosciences ( (ARTL) ) is now available.
On October 28, 2025, Artelo Biosciences entered into a Subscription Agreement with certain investors, resulting in the issuance and sale of convertible notes and warrants. The transaction involved an aggregate principal amount of $690,154.69 in notes and warrants to purchase 438,182 shares of common stock. This strategic move aims to strengthen the company’s financial position, with implications for its market operations and stakeholder interests, as it involves key directors and officers participating in the offering.
The most recent analyst rating on (ARTL) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Artelo Biosciences stock, see the ARTL Stock Forecast page.
Spark’s Take on ARTL Stock
According to Spark, TipRanks’ AI Analyst, ARTL is a Underperform.
Artelo Biosciences faces substantial financial hurdles with no revenue and continuous losses, heavily impacting its overall score. Technical indicators do not show a strong recovery trend, and the lack of new guidance from earnings calls further adds uncertainty. Valuation metrics are unfavorable due to negative earnings, making the stock less appealing to investors.
To see Spark’s full report on ARTL stock, click here.
More about Artelo Biosciences
Artelo Biosciences, Inc. operates in the biotechnology industry, focusing on the development of novel therapeutics. The company primarily engages in the research and development of proprietary compounds aimed at treating cancer, pain, and inflammation-related diseases.
Average Trading Volume: 103,255
Technical Sentiment Signal: Sell
Current Market Cap: $3.55M
For an in-depth examination of ARTL stock, go to TipRanks’ Overview page.